Tan Guangming, Yilmaz Asli, De Young Barry R, Behling Cynthia, Lehman Amy, Frankel Wendy L
Department of Pathology Ohio State University, Columbus, USA.
Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):193-7. doi: 10.1097/00129039-200409000-00002.
The distinction among inflammatory, benign, and malignant lesions of the biliary tract can at times be difficult. Several methods have been used, including immunohistochemistry (IHC), with variable success. We evaluated a panel of IHC stains to determine their utility in discriminating between bile duct lesions. Formalin-fixed, paraffin-embedded 4-microm sections from 12 inflammatory lesions, 10 bile duct adenomas, and 13 bile duct carcinomas were immunostained using a modified avidin-biotin-complex technique after epitope enhancement using antibodies for p53, Ki-67, and bcl-2. For p53 and bcl-2, greater than 1% of cells staining positive was interpreted as positive. The proliferation index was calculated by determining the number of Ki-67-positive cells in a 1000 cell count. In the inflammatory group, 0 of 12 reacted with anti-p53, 2 of 12 were positive with anti-bcl-2, and the proliferation index with was 22.9% +/- 3.9%. Two of 10 bile duct adenomas showed reactivity with anti-bcl-2, and none were decorated with anti-p53 or Ki-67. In the carcinoma group, 6 of 13 were positive with anti-p53, 9 of 12 were positive with anti-bcl-2, and the proliferation index was 35.3% +/- 5.5%. The proliferation rates differed significantly between groups (P < 0.05). The presence of bcl-2 and p53 immunoreactivity coupled with a high proliferative rate in a biliary tract lesion suggests a malignant process. A panel using these antibodies may be useful in difficult cases.
区分胆道的炎性、良性和恶性病变有时可能会很困难。已经使用了几种方法,包括免疫组织化学(IHC),但成功率各不相同。我们评估了一组免疫组织化学染色,以确定它们在鉴别胆管病变中的效用。使用针对p53、Ki-67和bcl-2的抗体进行表位增强后,采用改良的抗生物素蛋白-生物素复合物技术对来自12个炎性病变、10个胆管腺瘤和13个胆管癌的福尔马林固定、石蜡包埋的4微米切片进行免疫染色。对于p53和bcl-2,大于1%的细胞染色阳性被解释为阳性。通过在1000个细胞计数中确定Ki-67阳性细胞的数量来计算增殖指数。在炎性组中,12个样本中有0个与抗p53反应,12个中有2个抗bcl-2阳性,增殖指数为22.9%±3.9%。10个胆管腺瘤中有2个显示与抗bcl-2反应,没有一个被抗p53或Ki-67标记。在癌组中,13个中有6个抗p53阳性,12个中有9个抗bcl-2阳性,增殖指数为35.3%±5.5%。各组之间的增殖率差异显著(P<0.05)。在胆道病变中,bcl-2和p53免疫反应性的存在以及高增殖率提示为恶性过程。使用这些抗体的一组检测在疑难病例中可能有用。